Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Cocaine Vaccine: Human Laboratory Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Meets DSM-IV criteria for current cocaine dependence. The volunteer may meet criteria for other substance abuse, but not dependence (other than nicotine).~2. Primary route of cocaine administration is smoking.~3. Age 21-45.~4. Females must be surgically sterilized or post- menopausal~5. Able to give informed consent, and comply with study procedures.~Exclusion Criteria:~1. Dependence on substances other than cocaine or nicotine.~2. Judged to be noncompliant with study protocol.~3. History of autoimmune disease, immune deficiency or hypersensitivity to other vaccines. An HIV test must be negative.~4. Currently uses drugs intravenously~5. Currently taking any psychotropic medication~6. Laboratory tests that are clinically unacceptable to the study physician (BP \> 140/90; BUN, creatinine, LFTs \> 1.5 ULN; hematocrit \< 34 for women, \< 36 for men)~7. Blood or blood products given in the three months prior to vaccination~8. Other vaccines, including flu vaccine, given within 30 days of screening.~9. Ongoing active infection~10. Currently taking immunosuppressives -

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Low dose Vaccine (Type: EXPERIMENTAL): All participants were vaccinated four times: in week 1, 3, 5, and 9. Dose: 82ul
- High Dose Vaccine (Type: EXPERIMENTAL): All participants were vaccinated four times: in week 1, 3, 5, and 9. Dose: 360ul

Based on this trial design, predict the completion outcome and termination type (if applicable).